Actively Recruiting

Phase Not Applicable
Age: 18Years - 65Years
All Genders
ID07543328

The Clinical Efficacy of Prefrontal Transcranial Photobiomodulation (tPBM) in Patients With Treatment-Resistant Major Depressive Disorder: A Subgroup Analysis Focusing on Somatic Symptoms

Led by Taipei Veterans General Hospital, Taiwan · Updated on 2026-04-30

40

Participants Needed

1

Research Sites

12 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Researchers are evaluating the clinical effects of moderate-dose transcranial photobiomodulation (t-PBM) at two different frequencies (10 Hz and 40 Hz) in adults with treatment-resistant depression (TRD). The study particularly focuses on the subtype of depression dominated by somatic symptoms. It also aims to explore changes in neurophysiological measures related to brain activity and their connection to symptom improvement. Participants will be randomly assigned to receive t-PBM treatment at either 10 Hz or 40 Hz. Each session involves applying near-infrared light to the prefrontal cortex for 20 minutes, twice weekly over four weeks, totaling eight sessions. The study seeks to compare the effects of these two stimulation frequencies and observe their impact on depressive and somatic symptoms. During the study, participants will undergo clinical assessments before and after treatment, including depression rating scales (HDRS-17, MADRS), somatic symptom questionnaires, sleep quality evaluations, and overall functioning measures. Neurophysiological data will be collected using paired-pulse transcranial magnetic stimulation to assess brain excitability changes. The main outcome is the change in depression severity measured at baseline, after treatment, and at one-month follow-up. Safety and adherence will be monitored throughout the study, which is expected to last at least eight weeks per participant.

CONDITIONS

Brief Title

Transcranial Photobiomodulation (tPBM) for Somatic Symptoms in Treatment-Resistant Depression

Who Can Participate

Age: 18Years - 65Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Must have a current diagnosis of Major Depressive Disorder (MDD).
  • Clinical severity must be moderate or above, with a Clinical Global Impression-Severity (CGI-S) score greater than 4 and a 17-item Hamilton Depression Rating Scale (HDRS-17) total score of 18 or higher.
  • Must be currently receiving stable antidepressant treatment for at least four weeks but showing inadequate response (treatment-resistant).
  • Must have full behavioral capacity, normal intellectual functioning, and be able to understand and sign informed consent.
  • Age between 18 and 65 years.
Not Eligible

You will not qualify if you...

  • Diagnosis of Bipolar Disorder or Schizophrenia.
  • Current or recent Substance Use Disorder.
  • History of organic brain lesions such as neurodegenerative diseases, epilepsy, or stroke, or any medical condition affecting central nervous system function.
  • Abnormal intellectual functioning based on clinical judgment.
  • Currently pregnant.
  • Any other condition that would make participation unsuitable or prevent informed consent, as judged by the investigator.

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Treatment

Duration - 4 weeks

Participants receive transcranial photobiomodulation (tPBM) treatment targeting the prefrontal cortex twice a week to help improve symptoms of treatment-resistant depression.

Twice weekly visits for 4 weeks (8 total sessions)

Follow-up

Duration - 4 weeks

Participants are monitored for clinical outcomes and symptom changes after completing the treatment.

1 visit (in-person) at Week 8

Trial Site Locations

Total: 1 location

1

Taipei Veterans General Hospital

Taipei, Taiwan, 11217

Actively Recruiting

Loading map...

Research Team

J

Jia-Shyun Jeng

How is the study designed?

Study Type

INTERVENTIONAL

Masking

DOUBLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Similar Trials

A Randomized, Double-blind, Placebo-controlled Trial of ALTO...

Treatment-resistant Depression (TRD)

Actively Recruiting

48 locations

Esketamine With or Without Psychedelic Preparation and Integ...

Treatment-resistant Depression (TRD)

Actively Recruiting

2 locations

Assessment of Safety and Feasibility of Focused Ultrasound N...

Treatment-Resistant Depression

Actively Recruiting

1 location

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here